Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients

Hiroo Kumagai, Toshiya Ebata, Kenji Takamori, Katsumasa Miyasato, Taro Muramatsu, Hidetomo Nakamoto, Masanao Kurihara, Tomoji Yanagita, Hiromichi Suzuki

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid κ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients. Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 year. Methods: This open-label study examined the effects and adverse drug reactions (ADRs) of 52-week oral administration of nalfurafine hydrochloride (5 μg/day) in 211 hemodialysis patients with a treatment-resistant itch. Results: Of 211 patients, 145 completed the study as scheduled. The mean pruritus value assessed by the visual analogue scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, respectively, indicating a long-lasting efficacy. ADRs occurred in 103 patients (48.8%). Frequent ADRs were insomnia (sleep disturbance, 19.4%), constipation (7.1%) and increased blood prolactin (3.3%), similar to previous reports. Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused. After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation. Conclusions: Nalfurafine hydrochloride, orally administered at 5 μg/day for 52 weeks to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.

Original languageEnglish
Pages (from-to)175-183
Number of pages9
JournalAmerican Journal of Nephrology
Volume36
Issue number2
DOIs
Publication statusPublished - 2012 Aug 1

    Fingerprint

Keywords

  • Hemodialysis
  • Long-term efficacy and safety
  • Nalfurafine hydrochloride
  • Pruritus
  • κ-Receptor agonist

ASJC Scopus subject areas

  • Nephrology

Cite this

Kumagai, H., Ebata, T., Takamori, K., Miyasato, K., Muramatsu, T., Nakamoto, H., Kurihara, M., Yanagita, T., & Suzuki, H. (2012). Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology, 36(2), 175-183. https://doi.org/10.1159/000341268